PainReform (PainReform) Other Gross PPE : $0.04 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PainReform Other Gross PPE?

PainReform's Other Gross PPE for the quarter that ended in Mar. 2024 was $0.04 Mil.

PainReform's quarterly Other Gross PPE declined from Sep. 2023 ($0.04 Mil) to Dec. 2023 ($0.04 Mil) but then increased from Dec. 2023 ($0.04 Mil) to Mar. 2024 ($0.04 Mil).

PainReform's annual Other Gross PPE declined from Dec. 2021 ($0.05 Mil) to Dec. 2022 ($0.04 Mil) and declined from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.04 Mil).

PainReform Other Gross PPE Historical Data

The historical data trend for PainReform's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform Other Gross PPE Chart

PainReform Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

0.01

0.05

0.04

PainReform Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															0.04	0.04	0.04	0.04	0.04

PainReform Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

PainReform (PainReform) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Yigal Alon Street, Tel Aviv, ISR, 6744316

Website

https://www.painreform.com

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.